Government tightens oversight of GLP-1 drugs, flags risks amid rising demand; key details

The Centre has issued a detailed advisory on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision. Authorities are increasing regulatory surveillance and warning of strict action against violations in their sale or prescription.

This is a summary fetched via RSS. For the full story, use the link above.